Eurostars grant to fund stroke therapy development

Published: 29-Sep-2011
Research & Development Finance

NeuroVive and to-BBB each receive €500,000


Swedish drug developer NeuroVive Pharmaceutical and to-BBB, a Dutch brain drug delivery company, have been awarded €1m through the Eureka Eurostars programme for the joint development of drugs for stroke and other acute neurological conditions.

The firms have each received grants of approximately €500,000.

In this programme, NeuroVive's cyclosporin A for the treatment of neurological damage is combined with to-BBB's G-Technology to enhance delivery of this drug across the blood-brain barrier.

The two firms signed a strategic partnership in October 2010 and say the grant ‘solidifies and accelerates’ this partnership.

  • Companies:
  • to-BBB
  • NeuroVive Pharmaceutical
See more

You may also like

Research & Development

NeuroVive Pharmaceutical and A1M Pharma to collaborate on mitochondrial medicine

Read more
Initial purpose is to utilise the companies’ complementary scientific platforms within the framework of ongoing research projects

Trending Articles

  1. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  2. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  3. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  4. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  5. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

NeuroVive Pharmaceutical and A1M Pharma to collaborate on mitochondrial medicine

Initial purpose is to utilise the companies’ complementary scientific platforms within the framework of ongoing research projects
Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Manufacturing

Naobios and Sumagen sign exclusive partnership to develop HIV vaccine

Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Subscribe now